Nirsevimab Market
The market for Nirsevimab was estimated at $937 million in 2024; it is anticipated to increase to $1.34 billion by 2030, with projections indicating growth to around $1.82 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Nirsevimab Market Outlook
Revenue, 2024
$937M
Forecast, 2034
$1.71B
CAGR, 2025 - 2034
6.2%
The Nirsevimab industry revenue is expected to be around $995.0 million in 2025 and expected to showcase growth with 6.2% CAGR between 2025 and 2034. The market is gaining substantial momentum due to increasing awareness regarding respiratory syncytial virus prevention and the growing emphasis on infant immunization programs worldwide. Rising hospitalization rates associated with respiratory infections among newborns and high risk pediatric populations are encouraging healthcare systems to adopt advanced preventive biologics. Governments and healthcare organizations are also expanding pediatric vaccination and monoclonal antibody access programs to reduce seasonal respiratory disease burden. In addition, pharmaceutical companies are strengthening manufacturing capabilities and distribution networks to support broader product availability. Growing investments in pediatric infectious disease prevention and supportive regulatory approvals continue to reinforce the long term commercial importance of nirsevimab across global healthcare markets.
Nirsevimab is a long acting monoclonal antibody developed for the prevention of respiratory syncytial virus infections, particularly among infants and vulnerable pediatric populations. The therapy is designed to provide extended seasonal protection through a single dose administration, making it highly suitable for large scale immunization programs and hospital based pediatric care. Its major applications include prevention of lower respiratory tract infections caused by respiratory syncytial virus in newborns, premature infants, and high risk children. Increasing adoption of preventive healthcare strategies and rising focus on reducing pediatric hospitalization rates are significantly driving market demand. Recent trends include expanded regulatory approvals, integration into national immunization recommendations, and growing partnerships between pharmaceutical manufacturers and public healthcare agencies. Advancements in monoclonal antibody production technologies and broader pediatric healthcare investments are further supporting global commercialization and long term market expansion.
Market Key Insights
The Nirsevimab market is projected to grow from $936.9 million in 2024 to $1.71 billion in 2034. This represents a CAGR of 6.2%, reflecting rising demand across Preventive use for Respiratory Syncytial Virus, Immunoprophylaxis for At-risk Populations, and Pediatric Healthcare Optimization.
AstraZeneca, Sanofi, Pfizer are among the leading players in this market, shaping its competitive landscape.
U.S. and UK are the top markets within the Nirsevimab market and are expected to observe the growth CAGR of 4.0% to 6.0% between 2024 and 2030.
Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 7.1% to 8.6%.
Transition like Transition from Reactive Infant Respiratory Care Toward Preventive Immunization Strategies has greater influence in U.S. and UK market's value chain; and is expected to add $35 million of additional value to Nirsevimab industry revenue by 2030.
The Nirsevimab market is set to add $773 million between 2024 and 2034, with manufacturer targeting Research Institutes & Pharmaceutical Companies Application projected to gain a larger market share.
With
population increase and infant health concerns, and
Technological Advancements in Biopharmaceuticals, Nirsevimab market to expand 82% between 2024 and 2034.
Opportunities in the Nirsevimab
Growing integration of RSV prevention into national newborn immunization strategies is also creating significant opportunities for nirsevimab across European healthcare markets. Countries including France, Germany, and the United Kingdom are increasingly prioritizing preventive pediatric respiratory care to reduce seasonal hospital admissions. Long acting monoclonal antibody injections are expected to witness strong demand within hospital based neonatal and infant immunization programs. In addition, healthcare agencies are strengthening reimbursement support and preventive healthcare funding for pediatric biologics. Expanding collaboration between pharmaceutical manufacturers and public healthcare providers is further improving treatment accessibility and driving long term market growth across Europe.
Growth Opportunities in North America and Europe
North America represents one of the leading regional markets for nirsevimab due to strong pediatric healthcare infrastructure, high awareness regarding respiratory syncytial virus prevention, and growing adoption of preventive biologic therapies. The United States accounts for the majority of regional demand, supported by increasing investments in infant immunization programs and advanced neonatal care services. Rising hospitalization concerns associated with RSV infections are encouraging hospitals and healthcare agencies to integrate long acting monoclonal antibody therapies into preventive pediatric treatment strategies. The region also presents strong opportunities for biologics manufacturers through expanding reimbursement support and partnerships with pediatric healthcare networks. Competitive intensity remains high as pharmaceutical companies focus on regulatory approvals, manufacturing expansion, and commercialization agreements. In addition, increasing investments in pediatric infectious disease research and preventive healthcare modernization continue to strengthen North America’s long term market leadership within the global RSV prevention industry.
Europe holds a significant share in the nirsevimab market due to well established public healthcare systems, strong orphan and pediatric biologics support frameworks, and increasing emphasis on infant respiratory disease prevention. Countries including Germany, France, Spain, and the United Kingdom are actively integrating RSV prevention into broader immunization and neonatal healthcare programs. Growing awareness regarding seasonal respiratory infections among infants is supporting strong adoption of long acting monoclonal antibody therapies across pediatric hospitals and specialty healthcare centers. The region offers major opportunities through government funded immunization initiatives and expanding reimbursement coverage for preventive biologics. Competition is intensifying as multinational pharmaceutical companies strengthen partnerships with healthcare agencies and regional distributors. Furthermore, advancements in biologics manufacturing capabilities and increasing investments in preventive pediatric healthcare are reinforcing Europe’s position as a strategically important market for nirsevimab commercialization and long term industry expansion.
Market Dynamics and Supply Chain
01
Driver: Rising Infant Respiratory Infection Burden and Expansion of Preventive Immunization Programs
The increasing prevalence of respiratory syncytial virus infections among infants is also significantly driving demand for nirsevimab across global pediatric healthcare systems. Rising hospitalization rates associated with seasonal respiratory illnesses are also encouraging healthcare providers to prioritize preventive monoclonal antibody therapies for newborns and high risk infants. Simultaneously, expanding preventive immunization programs are also strengthening market adoption by integrating RSV protection into broader pediatric healthcare frameworks. Governments and healthcare agencies are also increasingly supporting large scale infant immunization initiatives to reduce healthcare system burden and intensive care admissions. In addition, advancements in long acting monoclonal antibody technologies are also improving treatment efficiency through single dose seasonal protection strategies. Growing collaboration between pharmaceutical manufacturers, pediatric hospitals, and public health organizations is also further accelerating commercialization opportunities and expanding access to preventive respiratory care solutions globally.
Continuous innovation in monoclonal antibody development is also emerging as a major driver for the nirsevimab market. Pharmaceutical companies are also increasingly investing in extended duration biologics designed to improve seasonal respiratory infection prevention among infants and vulnerable pediatric populations. Long acting antibody technologies are also gaining strong clinical preference because they reduce dosing frequency and enhance patient compliance within immunization programs. In addition, healthcare providers are also emphasizing preventive biologic solutions that lower hospitalization risks and improve healthcare resource management. Growing regulatory support for pediatric preventive therapies and expanding investments in biologics manufacturing infrastructure are also further strengthening the long term commercial potential of nirsevimab across developed and emerging healthcare markets.
02
Restraint: High Biologic Therapy Costs Limiting Accessibility Across Price Sensitive Healthcare Markets
The high cost associated with monoclonal antibody therapies remains a major restraint affecting broader adoption of nirsevimab, particularly in emerging and lower income healthcare markets. Public healthcare systems and insurance providers in cost sensitive regions often face budget limitations that restrict large scale inclusion of premium pediatric preventive biologics. For example, several developing countries prioritize essential vaccines over expensive seasonal immunoprophylaxis programs, reducing patient coverage rates. This pricing challenge limits market penetration and slows revenue expansion despite growing awareness regarding RSV prevention. In addition, hospitals and healthcare agencies may delay procurement decisions, affecting overall demand stability and commercialization opportunities for manufacturers.
03
Opportunity: Increasing Premature Infant Care Investments Within North American Specialty Hospitals and Growing Pediatric Preventive Biologics Demand Across Emerging Asia Pacific Healthcare Networks
Rising investments in neonatal intensive care and premature infant management programs are creating strong commercial opportunities for nirsevimab in North America. Specialty pediatric hospitals and advanced neonatal care centers are increasingly adopting long acting RSV preventive biologics for high risk infant populations. The United States is expected to remain the largest regional market due to strong healthcare spending and growing awareness regarding RSV associated hospitalization risks. In addition, healthcare systems are emphasizing preventive treatment approaches that improve clinical outcomes and reduce intensive care burden. Strategic partnerships between biologics manufacturers and pediatric healthcare networks are further supporting market expansion opportunities.
Asia Pacific is emerging as a major untapped opportunity for nirsevimab due to rapidly improving pediatric healthcare infrastructure and increasing awareness regarding infant respiratory infections. Countries such as China, India, and South Korea are strengthening immunization capabilities and expanding access to advanced biologic therapies within urban healthcare systems. Long acting monoclonal antibody formulations are expected to experience substantial demand growth in preventive RSV applications. Furthermore, governments and private healthcare providers are investing in pediatric disease prevention programs to reduce seasonal respiratory complications. Expanding pharmaceutical distribution partnerships and healthcare modernization initiatives are also supporting long term regional commercialization opportunities.
04
Challenge: Limited Awareness and Uneven Immunization Infrastructure Reducing Global Pediatric Adoption Rates
Limited awareness regarding respiratory syncytial virus prevention and inconsistent pediatric immunization infrastructure continue to restrain global market growth for nirsevimab. Many healthcare providers and caregivers in underserved regions still lack adequate understanding of RSV associated hospitalization risks and preventive treatment benefits. In addition, several developing healthcare systems have limited cold chain logistics and pediatric immunization capabilities, restricting efficient product distribution and administration. For instance, rural healthcare networks in emerging economies often experience delays in implementing advanced pediatric biologic programs. These infrastructure and awareness gaps reduce treatment accessibility, weaken seasonal demand consistency, and create uneven regional market expansion patterns for preventive RSV therapies.
Supply Chain Landscape
1
Raw Material Acquisition
Elementis PLCAshland Global Holdings
2
Drug Formulation
Sanofi PasteurAstraZeneca
3
Processing & Packaging
BectonDickinson and CompanySchott AG
4
Distribution & Sales
McKesson CorporationCardinal Health
1
Raw Material Acquisition
Elementis PLCAshland Global Holdings
2
Drug Formulation
Sanofi PasteurAstraZeneca
3
Processing & Packaging
BectonDickinson and CompanySchott AG
4
Distribution & Sales
McKesson CorporationCardinal Health
Use Cases of Nirsevimab in Preventive use for Respiratory Syncytial Virus & Immunoprophylaxis for At-risk Populations
Preventive use for Respiratory Syncytial Virus : Preventive use for respiratory syncytial virus represents the largest application segment for nirsevimab due to increasing focus on reducing infant respiratory infections and seasonal hospitalizations. Long acting monoclonal antibody injections are primarily administered through hospitals, neonatal care units, and pediatric immunization programs for newborns and infants entering RSV seasons. The therapy provides extended protection with a single dose, improving compliance and reducing healthcare burden compared to repeated preventive interventions. Rising awareness among healthcare providers regarding RSV associated complications is further strengthening demand. In addition, expanding government supported immunization recommendations and pediatric infectious disease prevention initiatives continue to support broader market adoption globally.
Immunoprophylaxis for At-risk Populations : Nirsevimab is increasingly being adopted for immunoprophylaxis among high risk pediatric populations, including premature infants and children with underlying respiratory or cardiac conditions. Injectable monoclonal antibody formulations are widely used in specialty pediatric hospitals and advanced neonatal healthcare centers to provide passive immunity against severe RSV infections. The therapy is gaining strong clinical preference because of its long duration of protection and simplified seasonal administration protocols. Growing investments in preventive pediatric healthcare and increasing awareness regarding high risk infant management are supporting market growth. Furthermore, healthcare systems are strengthening early intervention strategies to reduce intensive care admissions and long term treatment costs associated with RSV complications.
Pediatric Healthcare Optimization : Pediatric healthcare optimization is emerging as an important application area for nirsevimab as healthcare providers increasingly prioritize preventive care models and hospital resource efficiency. Long acting immunization solutions are being integrated into pediatric healthcare programs to reduce emergency admissions, shorten hospitalization durations, and improve seasonal respiratory disease management. Hospitals and public healthcare agencies are adopting nirsevimab within broader child healthcare strategies aimed at improving clinical outcomes and lowering healthcare expenditure. The therapy’s single dose administration approach also supports operational efficiency within immunization programs. In addition, rising investments in pediatric healthcare infrastructure and preventive biologics are creating favorable conditions for long term market expansion across developed and emerging regions.
Impact of Industry Transitions on the Nirsevimab Market
As a core segment of the Pharmaceutical industry,
the Nirsevimab market develops in line with broader industry shifts.
Over recent years, transitions such as Transition from Reactive Infant Respiratory Care Toward Preventive Immunization Strategies and Transition from Traditional Seasonal Prophylaxis Toward Long Acting Monoclonal Antibody Solutions have redefined priorities
across the Pharmaceutical sector,
influencing how the Nirsevimab market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition from Reactive Infant Respiratory Care Toward Preventive Immunization Strategies
The nirsevimab industry is driving a transition from reactive treatment of respiratory infections toward preventive pediatric immunization approaches. Healthcare providers are increasingly prioritizing early RSV prevention to reduce infant hospitalization rates and seasonal healthcare burden. This transition is significantly influencing associated industries such as pediatric biologics manufacturing, neonatal healthcare services, and vaccine distribution networks. For example, hospitals and public healthcare agencies are expanding seasonal infant immunization programs to improve respiratory disease management efficiency. In addition, pharmaceutical companies are increasing investments in long acting monoclonal antibody technologies, strengthening the broader preventive biologics ecosystem and accelerating innovation within pediatric infectious disease prevention markets.
02
Transition from Traditional Seasonal Prophylaxis Toward Long Acting Monoclonal Antibody Solutions
The market is witnessing a transition from conventional short duration RSV prophylaxis methods toward long acting monoclonal antibody therapies offering extended seasonal protection through simplified dosing strategies. This shift is improving treatment compliance and operational efficiency within pediatric healthcare systems and hospital immunization programs. The transition is also creating growth opportunities for biologics manufacturing companies, cold chain logistics providers, and specialty pharmaceutical distributors. For instance, increasing adoption of single dose RSV prevention therapies is encouraging healthcare systems to optimize neonatal care planning and reduce intensive care resource utilization. Furthermore, expanding investments in biologics production infrastructure are strengthening the commercial development of advanced pediatric preventive therapies globally.